Latest News for ITRM
Iterum Therapeutics said on Friday it has filed a petition in Ireland's High Court to wind up the drugmaker and was placed into provisional liquidation, with a hearing set for April 13.
DUBLIN and CHICAGO, March 27, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (in Provisional Liquidation) (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has filed a petition in the High Court in Ireland to wind up…
--Expanded Market Access and Patent Protection for ORLYNVAH™ --FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ITRM.
Senate Trading
No Senate trades found for ITRM.
U.S. House Trading
No House trades found for ITRM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.